Cancer Cachexia

Jan 16, 2026

Summary Cancer cachexia is a severe, multifactorial wasting syndrome affecting most advanced cancer patients, with no approved therapies in the US or Europe and only ADLUMIZ approved in Japan, underscoring a major unmet need. Despite the historical treatment gap, the cancer cachexia pipeline is now rapidly e...

May 03, 2024

Cancer cachexia, a debilitating condition characterized by severe weight loss and muscle wasting, complicates the battle against cancer. Approximately half of all patients with cancer experience cachexia. This rate of occurrence rises to as high as 86% in the last 1–2 weeks of life, with 45% of patients losing more...

Aug 03, 2020

The dynamics of the cancer cachexia market is expected to gain momentum as several companies are testing the waters, advancing cancer cachexia pipeline. More than half of the cancer patients suffer from cachexia, and over 30% of the cancer patients succumb to death due to complications that arise from cachexi...